MicrobiotiX strives to develop treatments
for global intractable diseases such as
multidrug-resistant bacterial infections,
autoimmune diseases and cancer.

We develop bacteriophage and microbiome based therapy against superbugs

MicrobiotiX strives to develop treatments
for global intractable diseases such as
multidrug-resistant bacterial infections,
autoimmune diseases and cancer. 

We develop bacteriophage and microbiome 

based therapy against superbugs


MICROBIOTIX

Microbiotics is a company that develops bacteriophage and microbiome based therapeutics targeting multidrug resistant pathogens. We aim to develop therapy for autoimmune diseases and various incurable diseases. We have the best technology in the field of bacteriophage, microbiome and a GMP facility for global advancement.

More

MICROBIOTIX

Microbiotics is a company that develops bacteriophage and microbiome based therapeutics targeting multidrug resistant pathogens. We aim to develop therapy for autoimmune diseases and various incurable diseases. We have the best technology in the field of bacteriophage, microbiome and a GMP facility for global advancement.

More

BACTERIOPHAGE

MICROBIOTIX

MicrobiotiX is developing a bacteriophage-based treatment to address the threat of multidrug-resistant bacteria. We are a venture company that possesses a bacteriophage library which has been collected and researched over 15 years. Our phage library includes 300 types of lytic bacteriophages that can target multidrug-resistant, gram-negative Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, and Escherichia coli. These bacterial strains are classified as the most urgent threat to global health by the World Health Organization (WHO) and the CDC.

More

BACTERIOPHAGE

MICROBIOTIX

MicrobiotiX is developing a bacteriophage-based treatment to address the threat of multidrug-resistant bacteria. We are a venture company that possesses a bacteriophage library which has been collected and researched over 15 years. Our phage library includes 300 types of lytic bacteriophages that can target multidrug-resistant, gram-negative Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, and Escherichia coli. These bacterial strains are classified as the most urgent threat to global health by the World Health Organization (WHO) and the CDC.

More

 GMP FACILITY

Quality Control

MicrobiotiX ensures the operation of high-quality process facilities integrated into the business plan to provide the highest quality products and services. We adher to regulatory standards to maintain world-class quality. It is our goal to provide excellence in quality of the product.

 GMP FACILITY

Quality Control

MicrobiotiX ensures the operation of high-quality process facilities integrated into the business plan to provide the highest quality products and services. We adher to regulatory standards to maintain world-class quality. It is our goal to provide excellence in quality of the product.

Strategic analysis

Internal audit
and monitoring

Improvement actions after review, to prevent recurrence

Calibration and process progress

Quality committee quality evaluation

Learn more



MICROBIOTIX

Gasan Digital Center Office & GMP
Address (08511) IT Mirae Tower, 33, Digital-ro 9-gil, Geumcheon-gu, Seoul (60-21 Gasan-Dong)
Office  304, 604, 606    GMP Facility 1105-1107
Tel 02. 6379. 2649    E-mail mx@microbiotix.net


MICROBIOTIX CO., LTD

IT Mirae Tower, 33, Digital-ro 9-gil, Geumcheon-gu, Seoul (60-21 Gasan-Dong, #304)  
TEL : 02. 6379. 2649
E-mail : mx@microbiotix.net

Copyright © MICROBIOTIX. All rights reserved.

INQUIRIES

MICROBIOTIX CO., LTD

IT Mirae Tower, 33, Digital-ro 9-gil, Geumcheon-gu, Seoul (60-21 Gasan-Dong, #304)

TEL : 02. 6379. 2649   l   E-mail : mx@microbiotix.net

Copyright © MICROBIOTIX. All rights reserved.